Krankenhaus Nordwest GmbH — Clinical Trial Site

133 Registered trials

61 Currently recruiting

Organisation

Krankenhaus Nordwest GmbH

Location

Frankfurt Am Main, Germany

Identifier

ORG-100041682

Address

Steinbacher Hohl 2-26, Praunheim, 60488, Germany

Departments

-
#2602: Institut für Klinisch-Onkologische Forschung (IKF)
Clinic for Pulmonology, Respiratory and Intensive Care Medicine, Gastroenterology, Cardiology
Clinic for thorax oncology
Department of Oncology and Hematology Krankenhaus Nordwest
Forschung der Krankenhaus Nordwest GmbH
II. Medizinische Klinik
IKF
IKF Hospital Northwest
Innere Medizin/Hämatologie/Onkologie
Institut fuer Klinisch- Onkologische Forschung (IKF)
Institut fuer Klinisch-Onkologische Forschung (IKF), DEU01-0
Institut fuer Klinisch-Onkologische Forschung
Institut fuer Klinisch-Onkologische Forschung (IKF)
Institut fuer Klinische Krebsforschung (IKF)
Institut Fuer KlinischOnkologische Forschung (IKF)
Institut für Klinisch Onkologische Forschung
Institut für Klinisch Onkologische Forschung am Krankenhaus Nordwest
Institut für Klinisch-Onkologische Forschung
Institut für Klinisch-Onkologische Forschung (IKF)
Institut für Klinisch-Onkologische Forschung (IKF
Institut für Klinisch-Onkologische Forschung (IKF)
Institut für Klinisch-Onkologische Forschung (IKF),UCT-Frankfurt
Institut für Klinisch-Onkologische Forschung am Krankenhaus Nordwest
Institut für Klinisch-Onkologische Forschung Universitäres Centrum für Tumorerkrankungen
Institut für Klinisch-Onkologische Krebsforschung
Institut für Klinische Krebsforschung IKF
Institute of Clincial Cancer Research
Institute of Clinical Cancer Research
Institute of clinical cancer research (IKF)
Institute of Clinical Cancer Research IKF
Institute of Clinical Cancer Research(IKF)
Klinik f. Onkologie und Hämatologie
Klinik für Hämatologie und Onkologie
Klinik für Onkologie und Hämatologie
Klinik für Onkologie, Sektion Thoraxonkologie
Klinik für Radioonkologie
Klinik für Thoraxonkologie
Klinik für Urologie
Klinisch-Onkologische Forschung
Klink für Onkologie und Hämatologie
n.a.
N/A
NA
Neurologische Klinik
Oncology and Hematology
Onkologie
Onkologie und Haematologie
Onkologie und Hämatologie - Medizinische Klinik II
Thoraxonkologie
UCT - University Cancer Center Frankfurt
Upper-GastroIntestinal-tract
Urology

Clinical trials at this site (133)

Search interface

BIOmarker driven intensification of cardiovascular RISK factor management in patients with high risk for recurrent cardiovascular EVENTs The… Recruiting

2024-511950-35-00 Acute Myocardial Infarction 5 2025-06-12
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants with Locally Advanced or Metastatic Cholangiocarc… Recruiting

2024-514261-19-00 Locally advanced, unresectable or metastatic cholangioc 9 2025-03-24
PRESERVE-003: ONC-392 (Study Drug) Versus Docetaxel (Standard of Care) in Metastatic Non-small Cell Lung Cancer That Progressed on PD-1/PD-L… Recruiting

2023-505311-20-01 Metastatic Non-Small Cell Lung Cancer 5 2025-03-21
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04
Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc… Recruiting

2024-513852-13-00 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic 5 2025-01-20
A trial to learn how safe Dato-DXd is when given with osimertinib, and how well it works compared to osimertinib alone in people who have ad… Recruiting

2023-509883-89-00 Epidermal growth factor receptor (EGFR) mutation-positi 5 2025-01-09
Substudy 06D: Combination Therapies in 2L Advanced Gastroesophageal Adenocarcinoma Recruiting

2023-509306-29-00 Gastroesophageal cancer 9 2024-09-26
HARMONi-3 Recruiting

2024-513087-26-00 Metastatic Non-small Cell Lung Cancer 5 2024-09-10
The CLEAN-DUCT / TRITICC-3 trial - Phase IIa, prospective, single arm, open label, non-randomized, multi-center pilot study of durvalumab (M… Recruiting

2023-509165-21-00 Extrahepatic cholangiocarcinoma (eCCA) 4 2024-08-08
Phase 2 Study of HER3-DXd in Locally Advanced or Metastatic Solid Tumors Recruiting

2023-507641-29-00 Locally Advanced or Metastatic Solid Tumors 4 2024-07-15
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients wit… Recruiting

2022-502404-73-00 Pancreatic ductal adenocarcinoma 4 2024-06-03
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Ch… Recruiting

2023-505660-11-00 Cholangiocarcinoma (LTT, 26.0) 5 2024-04-24
Short or long NAT for BR/LAPC (ADVANTAGE) Recruiting

2022-502117-29-00 Advanced pancreatic cancer 5 2023-10-19
A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF Class 1 and Class 2 alterations, in participan… Recruiting

2024-513578-23-00 Tumors harboring BRAF alterations 4 2023-03-21
Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced n… Recruiting

2023-509283-14-00 Advanced non-small cell lung cancer 1 2022-04-25
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoemboli… Recruiting

2024-512953-26-00 intermediate-stage hepatocellular carcinoma 5 2021-07-06
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Advanced Non-Small Cell Lung Cancer 10 2021-03-17
A clinical trial investigating the safety, tolerability, and therapeutic effects of BNT113 in combination with pembrolizumab versus pembroli… Recruiting

2024-512671-12-00 Unresectable head and neck squamous cell carcinoma, met 10 2021-03-05
HIPEC/FLOT9 - PREVENT Recruiting

2024-517300-10-01 Resectable diffuse type gastric and gastroesophageal ju 5 2020-12-17